Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries

By WebmasterJanuary 9, 2024December 12th, 2024No Comments

Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries

Previous PostSIRPant Immunotherapeutics Strengthens Board of Directors with Appointment of Roger Sawhney, M.D.
Next PostImmunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform